Prior development of a unique androgen-receptor (AR)-negative cell line (HH870) from organ-confined (T2b) human prostate cancer (CaP) enabled comparison of the gangliosides associated with normal and neoplastic prostate epithelial cells, organ-confined versus metastatic (DU 145, PC-3), and AR-negative versus AR-positive CaP cell lines. Resorcinol-HCl and specific monoclonal antibodies were used to characterize gangliosides on 2D-chromatograms, and to visualize them on the cell surface with confocal-fluorescence microscopy. AR-negative cells expressed GM1b, GM2, GD2, GD1a, and GM3. GM1a, GD1b, and GT1b were undetectable. GM1b and GD1a were more prominent in AR-negative than in AR-positive cells. PC-3 and HH870 cells were unique in the expression of O-acetylGD2 (O-AcGD2) and two alpha2,3-sialidase-resistant, alkali-susceptible GMR17-reactive gangliosides. Expression of GD1a, GM1b, doublets of GD3, GD2, and O-AcGD2, and the presence of an additional alkali-labile-14.G2a-reactive ganglioside, two alkali-susceptible, and three alkali-resistant GMR17-reactive gangliosides makes HH870 a potential component of a polyvalent-vaccine for active-specific immunotherapy of CaP.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.bbrc.2004.09.029 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Neoadjuvant chemotherapy before radical cystectomy in patients with organ-confined and non-organ-confined urothelial carcinoma.
Urol Oncol
January 2025
Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.
Introduction: Neoadjuvant chemotherapy (NAC) before radical cystectomy (RC) is guideline-recommended in patients with cT2-T4N0M0 urothelial carcinoma of urinary bladder (UCUB). However, no population-based study validated the survival benefit of NAC recorded in clinical trials in a stage-specific fashion. We addressed this knowledge gap.
View Article and Find Full Text PDFRetzius-sparing versus standard robot-assisted laparoscopic prostatectomy: A two-year patient-reported and oncological assessment.
Prostate
February 2025
Department of Urology, Europe Hospitals, Ste-Elisabeth, Brussels, Belgium.
Article Synopsis
- The study compares the two-year functional and oncological outcomes of Retzius-sparing robot-assisted laparoscopic prostatectomy (rsRALP) vs. standard robot-assisted laparoscopic prostatectomy (sRALP) in patients with localized prostate cancer.
- Results show that rsRALP significantly improves urinary function and quality of life over time, while sexual function differences were negligible after 12 months.
- Although rsRALP had some negative surgical margin characteristics, it did not affect biochemical recurrence rates after five years, indicating no significant difference in long-term oncological outcomes between the two methods.
Survival Rates in Trimodal Therapy Versus Radiotherapy in Urothelial Carcinoma of Urinary Bladder.
Eur Urol Focus
October 2024
Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.
Article Synopsis
- This study looked at two types of cancer treatment: Trimodal Therapy (TMT) and External Beam Radiation Therapy (EBRT) for bladder cancer patients.
- It found that TMT helped more patients live longer compared to EBRT, especially in those with earlier stages of cancer.
- However, TMT didn't show a survival advantage in patients with more advanced cancer stages.
Effect of Complete Transurethral Resection on Oncologic Outcomes After Radiation Therapy for Muscle-Invasive Bladder Cancer.
Int J Radiat Oncol Biol Phys
August 2024
Department of Urology, McGill University Health Centre, Montreal, QC, Canada. Electronic address:
Purpose: To compare the oncologic outcomes of patients with nonmetastatic muscle-invasive bladder cancer (MIBC) undergoing complete versus incomplete transurethral tumor resection (TURBT) before radiation therapy.
Methods And Materials: Patients with nonmetastatic MIBC who underwent curative-intent radiation therapy between 2002 and 2018 at 10 Canadian institutions were retrospectively evaluated. Inverse probability of treatment weighting was performed using baseline characteristics.
Temporal Trends and Cancer-Specific Mortality in Nonmetastatic Muscle-Invasive Urothelial Carcinoma of the Urinary Bladder Treated With Trimodal Therapy.
Clin Genitourin Cancer
August 2024
Cancer Prognostics and Health Outcomes Unit, Department of Urology, University of Montréal Health Center, Montréal, Québec, Canada.
Article Synopsis
- Trimodal therapy (TMT) is the recommended treatment for nonmetastatic urothelial carcinoma of the bladder, combining surgery, chemotherapy, and radiotherapy.
- An analysis of patient data from 2004-2020 showed an increase in TMT usage over time, with rates rising for both organ confined (OC) and non-organ confined (NOC) stages.
- Patients receiving contemporary TMT displayed better cancer-specific mortality-free survival (CSM-FS), with median survival rates improving in both OC and NOC groups compared to historical treatment periods.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!